News Headlines Article

Eli Lilly: Alzheimer’s drug may slow disease’s progress
USA Today

Eli Lilly and Co. hoped to salvage its Alzheimer’s drug solanezumab with new studies. Those hopes are still alive.

Results from the first of the studies Lilly is using to try to breathe new life into solanezumab suggest that the drug seems to delay the progress of Alzheimer’s disease in its early stages by 34%.

Lilly is releasing the much-anticipated study results Wednesday at the Alzheimer’s Association International Conference in Washington, D.C. The study results come with caveats. The drug didn’t reverse or stop the ravages of Alzheimer’s. And its disease-slowing impact applied only to patients with mild symptoms of Alzheimer’s, an incurable disease that destroys brain function.